DNA Nanosponge for Adsorption and Clearance of Intracellular miR-21 and Enhanced Antitumor Chemotherapy.

Zhang, Kaixiang; Liu, Junjie; Song, Qiaoli; Yang, Xue; Wang, Danyu; Liu, Wei; Shi, Jinjin; Zhang, Zhenzhong

Zhang, Kaixiang; Liu, Junjie; Song, Qiaoli; Yang, Xue; Wang, Danyu; Liu, Wei; Shi, Jinjin; Zhang, Zhenzhong.

Afiliación

Zhang K; School of Pharmaceutical Sciences, Collaborative Innovation Center of New Drug Research and Safety Evaluation, Key laboratory of Targeting Therapy and Diagnosis for Critical Diseases , Zhengzhou University , Zhengzhou 450001 , China.
Liu J; School of Pharmaceutical Sciences, Collaborative Innovation Center of New Drug Research and Safety Evaluation, Key laboratory of Targeting Therapy and Diagnosis for Critical Diseases , Zhengzhou University , Zhengzhou 450001 , China.
Song Q; School of Pharmaceutical Sciences, Collaborative Innovation Center of New Drug Research and Safety Evaluation, Key laboratory of Targeting Therapy and Diagnosis for Critical Diseases , Zhengzhou University , Zhengzhou 450001 , China.
Yang X; School of Pharmaceutical Sciences, Collaborative Innovation Center of New Drug Research and Safety Evaluation, Key laboratory of Targeting Therapy and Diagnosis for Critical Diseases , Zhengzhou University , Zhengzhou 450001 , China.
Wang D; School of Pharmaceutical Sciences, Collaborative Innovation Center of New Drug Research and Safety Evaluation, Key laboratory of Targeting Therapy and Diagnosis for Critical Diseases , Zhengzhou University , Zhengzhou 450001 , China.
Liu W; School of Pharmaceutical Sciences, Collaborative Innovation Center of New Drug Research and Safety Evaluation, Key laboratory of Targeting Therapy and Diagnosis for Critical Diseases , Zhengzhou University , Zhengzhou 450001 , China.
Shi J; School of Pharmaceutical Sciences, Collaborative Innovation Center of New Drug Research and Safety Evaluation, Key laboratory of Targeting Therapy and Diagnosis for Critical Diseases , Zhengzhou University , Zhengzhou 450001 , China.
Zhang Z; School of Pharmaceutical Sciences, Collaborative Innovation Center of New Drug Research and Safety Evaluation, Key laboratory of Targeting Therapy and Diagnosis for Critical Diseases , Zhengzhou University , Zhengzhou 450001 , China.

ACS Appl Mater Interfaces ; 11(50): 46604-46613, 2019 Dec 18.

Article en En | MEDLINE | ID: mdl-31763811

Asunto(s)

Neoplasias de la Mama/tratamiento farmacológico; ADN/genética; MicroARNs/genética; Oligonucleótidos Antisentido/farmacología; Adsorción/efectos de los fármacos; Animales; Apoptosis/efectos de los fármacos; Neoplasias de la Mama/genética; Neoplasias de la Mama/patología; Caspasa 3/genética; Citoplasma/genética; ADN/antagonistas & inhibidores; Doxorrubicina/química; Doxorrubicina/farmacología; Femenino; Regulación Neoplásica de la Expresión Génica/efectos de los fármacos; Humanos; Células MCF-7; Ratones; MicroARNs/antagonistas & inhibidores; Nanopartículas/química; Oligonucleótidos Antisentido/genética; Proteínas Proto-Oncogénicas c-bcl-2/genética; ARN Circular/genética; Ensayos Antitumor por Modelo de Xenoinjerto

Palabras clave

DNA nanosponge; antisense oligonucleotide; cell apoptosis; enhanced chemotherapy; miRNA-21

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / ADN / Oligonucleótidos Antisentido / MicroARNs Límite: Animals / Female / Humans Idioma: En Revista: ACS Appl Mater Interfaces Asunto de la revista: BIOTECNOLOGIA / ENGENHARIA BIOMEDICA Año: 2019 Tipo del documento: Article País de afiliación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google